Octagam 10% (Human Normal Immunoglobulin)

Human Normal Immunoglobulin supplies a broad spectrum of pooled IgG antibodies that neutralize pathogens, bind auto‑antibodies, regulate Fcγ receptors, inhibit complement activation, and suppress pro‑inflammatory cytokines, thereby restoring immune homeostasis.

The dosing regimen for Octagam 10% is individualized. The prescribing clinician determines the dose, infusion rate, and treatment schedule based on the specific indication, patient weight, and clinical response.

Octagam 10% may be used during pregnancy or lactation only if clearly needed. The potential benefits should be weighed against any unknown risks, and the decision should be made by the treating physician in consultation with the patient.

To order Octagam 10%, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and import documentation.

Octagam 10% is a 10% concentration IVIG derived from EU‑sourced plasma, offering comparable efficacy to other licensed IVIGs. Differences among products may include concentration, stabilizers, and manufacturing processes, which can affect infusion volume, tolerability, and storage requirements.

Octagam 10% must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

Octagam 10% is administered intravenously by a qualified healthcare professional. The infusion is given through a dedicated IV line, typically over several hours, with the rate adjusted according to patient tolerance and clinical guidelines.

Serious risks include thromboembolic events, acute renal failure, aseptic meningitis, hemolytic anemia, and severe allergic reactions such as anaphylaxis. Patients should be monitored closely during and after infusion for any signs of these complications.

Octagam 10% is contraindicated in patients with known severe IgA deficiency who have experienced anaphylactic reactions to immunoglobulins, and in individuals with uncontrolled hypercoagulable states or active severe infections without appropriate treatment.